Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Johnson & Johnson to appeal opioid judgment in Oklahoma
The Company is confident it has strong grounds to appeal this decision. The judgment disregards the Company’s compliance with federal and state laws, the unique role its medicines
The Company is confident it has strong grounds to appeal this decision. The judgment disregards the Company’s compliance with federal and state laws, the unique role its medicines
The latest FDA approval is the third for Taltz with the first one coming in 2016 for the treatment of adults with moderate to severe plaque psoriasis. The
The deal signed last month by the US-based Gilead Sciences and Galapagos has been cleared under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 by the US Federal Trade
In the Phase 2 portion of the Phase 2/3 study, a multicenter, randomized double-blind trial, all patients received docetaxel 75 mg/m2 on Day 1. Patients were randomly assigned
The financing comes from new investors including OCV Partners, Susquehanna International Group (SIG), Symbiosis LLC and the Trans-Pacific Technology Fund, as well as existing investors, including Avenir Growth
The FDA has advised Seelos that it may proceed with the proposed clinical trial SLS-005-201 for Mucopolysaccharidosis type III (Sanfilippo syndrome). “We are very pleased to have received
Cabotegravir is an investigational integrase inhibitor (INI) developed by ViiV Healthcare, while Edurant (rilpivirine) has been developed by Janssen as a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the
Oncorus, which is headquartered in Cambridge, Massachusetts, is an oncolytic virus company. It is engaged in advancing a portfolio of locally and systemically administered (IV) OV therapies based
The submission is based on the results from the landmark Phase III CREDENCE study1 which evaluated the efficacy and safety of canagliflozin versus placebo in this high-risk patient
As per the terms of the deal, Bayer will receive $5.3bn (£4.37bn) in cash and will be issued $2.3bn (£1.9bn) worth shares in the US-based Elanco Animal Health.